Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaRichard R. Furman, Susan O’Brien, Bertrand Coiffier et al.|New England Journal of Medicine|2014Cited by 1.7k
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David A. Cairns et al.|New England Journal of Medicine|2023Cited by 155
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibitionJianguo Zhuang, Andrew R. Pettitt|Haematologica|2009Cited by 73
<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndromeToby A. Eyre, Anna Schuh, Ruth Clifford et al.|British Journal of Haematology|2016Cited by 66
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Sean Girvan et al.|New England Journal of Medicine|2025Cited by 26